What is Exagen?
Exagen is a United States-based life sciences entity focused on developing and commercializing sophisticated diagnostic testing solutions tailored for autoimmune diseases. Through its AVISE brand, the company provides a suite of laboratory tests designed to enhance the accuracy and timeliness of disease detection and management for healthcare providers. By leveraging proprietary biomarkers and innovative testing technologies, Exagen aims to offer clarity in clinical decision-making, enabling more effective treatment strategies for conditions such as lupus and rheumatoid arthritis. The company's commitment to patient-centered care and scientific discovery drives its pursuit of improved patient outcomes through research-driven diagnostic innovation.
How much funding has Exagen raised?
Exagen has raised a total of $258.3M across 15 funding rounds:
Series D
$5M
Debt
$25M
Debt
$4M
Debt
$1.8M
Debt
$3M
Series E
$16.8M
Debt
$2.1M
Series F
$23M
Debt
$25M
Private Equity
$22.6M
Stock Offering
$58M
Stock/Share Issuance
$20.2M
Series D (2013): $5M featuring CRG L.P.
Debt (2013): $25M backed by Capital Royalty Partners
Debt (2014): $4M with participation from Sun Mountain Capital
Debt (2015): $1.8M, investors not publicly disclosed
Debt (2015): $3M, investors not publicly disclosed
Series E (2016): $16.8M, investors not publicly disclosed
Debt (2016): $2.1M, investors not publicly disclosed
Series F (2017): $23M, investors not publicly disclosed
Debt (2017): $25M led by Innovatus Capital Partners, LLC
Private Equity (2019): $22.6M supported by Tullis Health Funds, H.I.G. BioHealth Partners, Sun Mountain, and Hunt Holdings
Stock Issuance/Offering (2019): $58M featuring Undisclosed
Stock/Share Issuance (2025): $20.2M, investors not publicly disclosed
Key Investors in Exagen
CRG L.P.
CRG L.P. is a global investment firm specializing in credit and select equity investments across consumer health, life sciences, and healthcare services & IT, providing flexible growth capital solutions.
Epic Ventures
Epic Ventures is an early-stage venture capital fund focused on investing in patent-based hard science and deep tech startups, providing capital and business development support to help companies grow from research stage to unicorn status.
Cottonwood Technology Fund
Cottonwood Technology Fund is an early-stage venture capital fund focused on investing in patent-based hard science and deep tech startups primarily located in the Southwest USA and Northern Europe, specializing in key enabling technologies.
What's next for Exagen?
The recent major strategic investment signifies a pivotal moment for Exagen, positioning it for accelerated growth and further innovation in the competitive diagnostics market. This capital infusion is expected to bolster the company's research and development initiatives, potentially expanding its portfolio of diagnostic tests and enhancing its market reach. As Exagen continues to refine its offerings for autoimmune disease management, this strategic backing will likely support efforts to scale operations, strengthen partnerships with healthcare providers, and solidify its role as a key player in advancing diagnostic accuracy and patient care within the life sciences sector.
See full Exagen company page
